We are live on
!
Find out more
SCM
Sarissa Capital Management Portfolio holdings
AUM
$158M
1-Year Est. Return
103.7%
This Fund
S&P 500
This Quarter
Est. Return
+9.13%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$290M
AUM Growth
+$23.4M
(+8.8%)
Cap. Flow
+$7.37M
Cap. Flow
% of AUM
2.54%
Top 10 Holdings %
Top 10 Hldgs %
96.57%
Holding
18
New
6
Increased
3
Reduced
1
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BRLI
BIO-REFERENCE LABS INC-NEW-
BRLI
|
+$26.1M |
| 2 |
Quest Diagnostics
DGX
|
+$4.02M |
| 3 |
Traws Pharma
TRAW
|
+$3.61M |
| 4 |
Labcorp
LH
|
+$3.51M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$2.29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$13.3M |
| 2 |
AbbVie
ABBV
|
+$13.2M |
| 3 |
Pfizer
PFE
|
+$12.6M |
| 4 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$322K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 76.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARIA
1
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $96.7M | 33.3% |
12,000,000
| – | – |
|
|
2
Quest Diagnostics
DGX
$25.7B
| $44.9M | 15.46% |
775,000
+75,000
| +11% | +$4.02M |
|
|
BRLI
3
DELISTED
BIO-REFERENCE LABS INC-NEW-
BRLI
| $35.5M | 12.21% |
1,280,984
+995,684
| +349% | +$26.1M |
|
|
IDIX
4
DELISTED
IDENIX PHARMACEUTICALS INC
IDIX
| $30.5M | 10.49% |
5,050,100
| – | – |
|
5
Merck
MRK
$322B
| $22.7M | 7.82% |
419,200
| – | – |
|
|
MNK
6
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $17.4M | 6% |
274,895
-5,105
| -2% | -$322K |
|
|
VVUS
7
DELISTED
Vivus Inc
VVUS
| $15.3M | 5.26% |
257,394
| – | – |
|
|
RPRX
8
DELISTED
Repros Therapeutics Inc.
RPRX
| $9.95M | 3.42% |
560,600
+101,092
| +22% | +$1.96M |
|
|
AVEO
9
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| $3.84M | 1.32% |
257,076
| – | – |
|
|
10
Labcorp
LH
$25B
| $3.71M | 1.28% |
+44,027
| New | +$3.51M |
|
|
ITCI
11
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $2.3M | 0.79% |
+126,695
| New | +$2.29M |
|
|
12
Traws Pharma
TRAW
$6.85M
| $2.22M | 0.76% |
+6
| New | +$3.61M |
|
13
Enanta Pharmaceuticals
ENTA
$366M
| $2M | 0.69% |
+50,000
| New | +$1.82M |
|
|
KIN
14
DELISTED
Kindred Biosciences, Inc.
KIN
| $1.89M | 0.65% |
+101,825
| New | +$1.94M |
|
15
Gyre Therapeutics
GYRE
$641M
| $1.56M | 0.54% |
+418
| New | +$1.55M |
|
|
16
AbbVie
ABBV
$443B
| – | – |
-250,000
| Closed | -$13.2M |
|
|
17
Bristol-Myers Squibb
BMY
$133B
| – | – |
-250,000
| Closed | -$13.3M |
|
|
18
Pfizer
PFE
$143B
| – | – |
-432,140
| Closed | -$12.6M |
|
Similar funds
4A
DAM
PCP
CF
HEM
SF
AC
EP
Sarissa Capital Management's Q1 2014 Portfolio in Review
As of Q1 2014, Sarissa Capital Management held 18 positions worth $290M, up 8.8% from $267M the previous quarter. Its ten largest holdings account for 97% of the portfolio.
Sarissa Capital Management's Q1 2014 filing shows 6 new, 3 increased, 1 reduced and 3 closed positions. Its largest new stake was Traws Pharma: 6 shares worth $2.22M. The largest sale was Bristol-Myers Squibb, an estimated $13.3M.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 86% a quarter earlier.
- Sarissa Capital Management's largest Q1 2014 buy was Traws Pharma: 6 shares worth $2.22M.
- Sarissa Capital Management added most to BIO-REFERENCE LABS INC-NEW- in Q1 2014, an estimated $26.1M increase.
- Sarissa Capital Management's biggest Q1 2014 reduction was MALLINCKRODT PUBLIC LIMITED COMPANY, cutting an estimated $322K.
- Sarissa Capital Management fully exited Bristol-Myers Squibb in Q1 2014, selling an estimated $13.3M.
- Sarissa Capital Management's ten largest holdings make up 97% of its $290M portfolio in Q1 2014.
- Sarissa Capital Management opened 6 new positions and closed 3 in Q1 2014.
- Sarissa Capital Management's portfolio value rose 8.8% quarter-over-quarter to $290M.
Based on Sarissa Capital Management's 13F filing for Q1 2014, filed 15 May 2014.